Jeff Hutchins, PhD
Chief Development Officer
Dr. Hutchins was most recently Chief Science and Chief Operating Officer at Heat Biologics (Nasdaq: HTBX) where he guided a focus on cancer and infectious disease directed therapies that activate the human immune system. Prior to joining Heat, Dr. Hutchins served as Vice President of Preclinical Research at Peregrine Pharmaceuticals, Inc., a biopharmaceutical company developing therapeutics to fight cancer and infectious diseases. Dr. Hutchins also served as Vice President, Preclinical Development at Inhibitex, Inc., which was acquired by Bristol-Myers Squibb. Earlier, Dr. Hutchins held several senior scientist positions in discovery research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College.
​
Dr. Hutchins earned a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center, and conducted postdoctoral training at the University of Southern California’s Department of Microbiology at the Norris Cancer Center. Dr. Hutchins’ publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology.